Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.

When analyzing by arm, responses were also more frequent in smaller than larger tumors in Arm B (50 patients who received Depatux-M with temozolomide, response rate 24% vs 0%, P = .089 two-sided) and Arm C (60 patients who received Depatux-M alone, response rate 10% vs 0%, P = .287) but did not reach statistical significance in this underpowered posthoc exploratory subset analysis.

also in 111,027 other papers